Compare IDEXX Laboratories, Inc. (IDXX) vs Intel Corp (INTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Intel Corp — how do they compare? IDEXX Laboratories, Inc. trades at $571.49 (market cap $46.22B), while Intel Corp trades at $102.3 (market cap $492.85B). The key difference: Intel Corp is far larger — about 10.7× IDEXX Laboratories, Inc.'s market cap, and Intel Corp pays a 2.24% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | INTC | |
|---|---|---|
Market Cap | $46.22B | $492.85B |
Sector | Health | Technology |
52-Week High | $766.68 | $140.94 |
52-Week Low | $526.44 | $21.81 |
Enterprise Value | $47.12B | $513.66B |
Volume | — | 43,552,012 |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Intel (INTC) trades at $100.51, up 3.07% today, with a bullish technical signal and recent earnings beats. Revenue grew 25% year-over-year in Q2 2026, driven by data center and AI segments, though net income margins remain negative. The company recently upsized a stock offering to $20 billion to fund AI and manufacturing investments, causing some investor concern over dilution but supporting long-term growth initiatives.
Outlook is mixed: strong revenue growth and analyst consensus price target of $116.67 suggest upside, but high valuation ratios, negative profitability, and execution risks in the capital-intensive foundry business pose challenges. Investor sentiment is cautiously optimistic amid the AI-driven turnaround narrative.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
